Welcome to our dedicated page for Scienture Holdings news (Ticker: SCNX), a resource for investors and traders seeking the latest updates and insights on Scienture Holdings stock.
Scienture Holdings, Inc. (NASDAQ: SCNX) generates news that centers on specialty pharmaceutical product launches, commercialization milestones, financing activities and corporate governance developments. Through its wholly owned subsidiary Scienture, LLC, the company focuses on novel specialty products that address unmet market needs, and its announcements frequently highlight progress in bringing these therapies to patients, physicians and healthcare institutions.
Recent Scienture news has emphasized Arbli™, which the company describes as the first and only oral liquid formulation of losartan approved by the U.S. FDA and the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium. Updates have covered the start of commercial sales and fulfillment of initial orders, availability of Arbli™ through full-line wholesalers nationwide, multiple group purchasing organization (GPO) agreements providing access to thousands of healthcare institutions, and the addition of Arbli™ to formularies of major national health plans.
Another major news theme is REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, which Scienture presents as the highest dosage naloxone HCl nasal spray approved by the FDA for emergency treatment of known or suspected opioid overdose. Company releases have described exclusive U.S. commercialization rights, FDA approval, and the issuance of an Orange Book-listable U.S. patent that may support the product’s U.S. commercialization.
Investors following SCNX news can also expect updates on SEC filings, equity distribution arrangements, secured financing transactions, conversion of prior debentures into common stock, and notices related to Nasdaq listing requirements. Governance and shareholder matters, such as annual meeting proposals, equity incentive plan amendments and bylaw changes, are reported through both press releases and current reports on Form 8-K. This news feed offers a centralized view of Scienture’s commercial progress, regulatory developments and capital markets activity.
Scienture (NASDAQ: SCNX) reported Q1 2026 revenue of approximately $56 thousand, up about 449% year-over-year from $10 thousand. Gross profit rose to about $54 thousand with gross margin expanding to 95.6% from 6.6%, while net loss widened to roughly $3.4 million.
Key updates include a third patent for Arbli oral suspension extending expected exclusivity to 2041, an Orange Book-listable patent for REZENOPY 10 mg nasal spray, and GPO agreements giving REZENOPY access to over 5,000 U.S. healthcare institutions. Scienture also secured $11.0 million in non-dilutive debt financing to support commercialization and R&D.
Scienture (NASDAQ: SCNX) secured $11.0 million in non-dilutive debt financing via two promissory notes: an $8.42 million unsubordinated note and a $3.0 million secured note. Proceeds will fund commercialization of FDA-approved Arbli and REZENOPY and advance multiple R&D programs; the company reiterated an expectation to reach profitability in 2027.
Scienture (NASDAQ: SCNX) announced U.S. Patent No. 12,605,365 for ARBLI™ (losartan potassium) oral suspension, issued April 21, 2026, providing protection through October 7, 2041. ARBLI™ is the first FDA-approved ready-to-use liquid losartan aimed at pediatric and geriatric patients within a roughly $241M U.S. losartan market (≈72M prescriptions annually).
The company reports early commercial progress via increased physician awareness, expanding formulary access, and wider distribution, and says the new patent strengthens long-term exclusivity and commercialization prospects.
Scienture (NASDAQ: SCNX) received a 180-calendar day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement, extending the deadline to October 12, 2026. The company’s common stock will continue trading on the Nasdaq Capital Market.
Nasdaq found Scienture met all other listing criteria except the bid price; the company may cure the deficiency by raising the bid above $1.00 for ten consecutive business days or, if necessary, by effecting a reverse stock split. Scienture cited recent commercial momentum, including FDA approval and launch activity.
Scienture (NASDAQ: SCNX) provided its 2025 annual shareholder update on April 6, 2026, highlighting commercialization progress and financial results. Revenue rose 216% to $431,609; gross margin expanded to 76.8% (+7,240 bps). The company launched Arbli in Sept 2025 and expects to launch REZENOPY in Q2 2026.
Year-end cash was ~$6.7M with positive working capital ~$5.2M; net loss from continuing operations was ~$41.5M including a $26.3M non-cash impairment. Nasdaq minimum bid compliance action deadline is April 13, 2026.
Scienture (NASDAQ: SCNX) reported 2025 results on March 30, 2026, driven by the commercial launch of Arbli™. Net revenue rose 216% to $431,609 and gross margin expanded 7,240 basis points to 76.8%. The year included a $26.3M one-time, non-cash impairment, leaving net loss from continuing operations of $41.5M. As of December 31, 2025, cash totaled $6.7M with $5.2M positive working capital. Operationally, Scienture secured multiple PBM/GPO and formulary agreements for Arbli™ and REZENOPY™, obtained Orange Book-listable patents for both products, and established a BlinkRx collaboration to support patient access.
Scienture (NASDAQ: SCNX) announced GPO agreements giving REZENOPY™ (naloxone HCl) Nasal Spray 10 mg access to more than 5,000 healthcare institutions, representing potential penetration of roughly 60% of the U.S. institutional market. REZENOPY™ is the highest-dose FDA-approved naloxone nasal spray.
IQVIA (MAT Jan 2026) shows the U.S. naloxone market at $141M annual sales with 9.4M prescription units, highlighting a defined commercial opportunity for broader institutional adoption through hospitals, EMS, and rehabilitation centers.
SCIENTURE (NASDAQ: SCNX) provided a commercial update on ARBLI™, the first FDA-approved ready-to-use oral suspension of losartan, reporting payer and distribution wins that expand access across retail, institutional and managed-care channels.
Key achievements include PBM-led GPO rebates, Institutional GPO deals covering >2,500 facilities, formulary inclusion for >100 million covered lives, a BlinkRx collaboration, reaffirmed REZENOPY™ commercial launch in Q2 2026, and a year-end cash position of approximately $7.0 million after debt reduction.
SCIENTURE (NASDAQ: SCNX) announced issuance of U.S. Patent No. 12,514,854 B2, an Orange Book-listable patent covering REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, effective Jan 6, 2026 and expiring Feb 5, 2041. Scienture holds exclusive U.S. commercialization rights under a March 2025 agreement with Summit, which will manufacture and supply the product. REZENOPY™ received FDA approval on Apr 19, 2024 and is the highest-dosage FDA-approved naloxone nasal spray. IQVIA (MAT Sep 2025) reports U.S. naloxone sales of approximately $154 million and 9.3 million units, highlighting the market opportunity.
SCIENTURE (NASDAQ: SCNX) provided an update on the commercial launch of REZENOPY® (naloxone HCl) Nasal Spray 10 mg, the highest-strength FDA-approved naloxone product. Scienture acquired exclusive U.S. commercialization rights in March 2025 and notes FDA approval occurred on April 19, 2024. IQVIA data (MAT September 2025) shows the U.S. naloxone market at approximately $154 million in annual sales and 9.3 million units annually.
Manufacturing is reported to be on track with product readiness expected in Q1 2026, wholesale loading in Q1 2026, and commercial availability beginning in early Q2 2026.